Human and animal studies suggest that both traumatic nerve injury and toxic challenge with
chemotherapeutic agents involves the reorganization of neural circuits in the brain …

Paclitaxel, one of the most commonly used cancer chemotherapeutic drugs, effectively
extends the progression-free survival of breast, lung, and ovarian cancer patients. However …

Chemotherapy-induced neuropathy (CIN) is one of the most common complications of
cancer treatment with sensory dysfunctions which frequently include pain. The mechanisms …

Paclitaxel-induced sensory neuropathy is a problematic side-effect of cancer chemotherapy.
Previous studies in rodents have shown paclitaxel treatment to have many effects on …

Paclitaxel-induced peripheral neuropathy (PN) can be a significant problem for patients
receiving chemotherapeutic regimens for the treatment of breast, ovarian, and lung cancer …

Chemotherapy-induced neuropathic pain is a serious adverse effect of chemotherapeutic
agents. Clinical evidence suggests that stress is a risk factor for development and/or …

The mechanisms underlying chemotherapy-induced peripheral neuropathy have yet to be
fully elucidated, but primary afferent neurons have emerged as an especially vulnerable …

The clinical use of the antineoplastic agent paclitaxel (Taxol) is significantly limited in its
effectiveness by a dose-related painful peripheral neuropathy. To evaluate underlying …

Peripheral neuropathy is a major side effect following treatment with the cancer
chemotherapeutic drug paclitaxel. Whether paclitaxel-induced peripheral neuropathy is …

Objective: The aim of this study was to elucidate any electrophysiological changes that may
contribute to the development of neuropathic pain during treatment with the anticancer drug …